Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Libido Clear all
Completed Not applicable Interventional

WISH, Feasibility of a Factorial Design

NCT07023822
View directory record Official record
Conditions
Breast Cancer, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder, Body Image
Interventions
Hyaluronic acid (HLA) Vaginal Moisturizer, Polycarbophil Vaginal Moisturizer, Hypnotic Relaxation, Progressive Muscle Relaxation (PMR)
Device · Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Testosterone Cream, Estring
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

NCT00467259
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
115
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 8, 2026, 2:10 AM EDT
Withdrawn Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 8, 2026, 2:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of Four Supplements on Improving Readiness for Intimacy

NCT05862519
View directory record Official record
Conditions
Libido, Intimacy, Gastrointestinal Issues
Interventions
Reset, Stay Ready Fiber, Libido, Testosterone supplement
Dietary Supplement
Lead sponsor
906 CMVI Holdings
Industry
Eligibility
18 Years to 44 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
View directory record Official record
Conditions
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions
bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 8, 2026, 2:10 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360529
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • South Birmingham, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Study of LY2452473 and Tadalafil

NCT01401543
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
LY2452473, Tadalafil, LY900010
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 8, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Hypoactive Sexual Desire Disorder in Males

NCT04002661
View directory record Official record
Conditions
Low Libido
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years to 69 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00996164
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

NCT00075855
View directory record Official record
Conditions
Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic testosterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 8, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional Results available

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT01103362
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
88
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Women's Interventions for Sexual Health: WISH

NCT05692960
View directory record Official record
Conditions
Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
Interventions
Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
Other · Device
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

NCT01816295
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone Solution, Placebo Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Homewood, Alabama • Chandler, Arizona • Glendale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 8, 2026, 2:10 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction

NCT02865187
View directory record Official record
Conditions
Female Sexual Dysfunction, Polycystic Ovary Syndrome
Interventions
Vitamin D, Hormonal contraception
Dietary Supplement · Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Dayton, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

NCT01188603
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin 100 mg dose every evening
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Wichita, Kansas • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 8, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 8, 2026, 2:10 AM EDT